These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 20217540)

  • 1. Medical devices for the treatment of eye diseases.
    Yasukawa T; Ogura Y
    Handb Exp Pharmacol; 2010; (197):469-89. PubMed ID: 20217540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraocular sustained drug delivery using implantable polymeric devices.
    Yasukawa T; Ogura Y; Sakurai E; Tabata Y; Kimura H
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2033-46. PubMed ID: 16263193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug delivery from ocular implants.
    Yasukawa T; Ogura Y; Kimura H; Sakurai E; Tabata Y
    Expert Opin Drug Deliv; 2006 Mar; 3(2):261-73. PubMed ID: 16506952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel drug delivery systems for retinal diseases. A review.
    Lee SS; Robinson MR
    Ophthalmic Res; 2009; 41(3):124-35. PubMed ID: 19321933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug delivery methods for posterior segment disease.
    Hsu J
    Curr Opin Ophthalmol; 2007 May; 18(3):235-9. PubMed ID: 17435432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery to the posterior segment of the eye.
    Thrimawithana TR; Young S; Bunt CR; Green C; Alany RG
    Drug Discov Today; 2011 Mar; 16(5-6):270-7. PubMed ID: 21167306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Potential of liposomes for the intravitreal injection of therapeutic molecules].
    Bochot A; Lajavardi L; Camelo S; Bourges JL; Behar-Cohen F; de Kozak Y; Fattal E
    Ann Pharm Fr; 2011 Mar; 69(2):100-7. PubMed ID: 21440102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular implants for extended drug delivery: therapeutic applications.
    Bourges JL; Bloquel C; Thomas A; Froussart F; Bochot A; Azan F; Gurny R; BenEzra D; Behar-Cohen F
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1182-202. PubMed ID: 17107737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug delivery systems for vitreoretinal diseases.
    Yasukawa T; Ogura Y; Tabata Y; Kimura H; Wiedemann P; Honda Y
    Prog Retin Eye Res; 2004 May; 23(3):253-81. PubMed ID: 15177203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in sustained-release drug delivery system for treatment of posterior segment eye diseases].
    Sun SM; Cheng LY
    Zhonghua Yan Ke Za Zhi; 2013 Sep; 49(9):847-50. PubMed ID: 24330936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug delivery to target the posterior segment of the eye].
    Behar-Cohen F
    Med Sci (Paris); 2004; 20(6-7):701-6. PubMed ID: 15329823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraocular sustained-release delivery systems for triamcinolone acetonide.
    Mansoor S; Kuppermann BD; Kenney MC
    Pharm Res; 2009 Apr; 26(4):770-84. PubMed ID: 19184374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
    Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
    Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations.
    Loftsson T; Sigurdsson HH; Konrádsdóttir F; Gísladóttir S; Jansook P; Stefánsson E
    Pharmazie; 2008 Mar; 63(3):171-9. PubMed ID: 18444504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
    Del Amo EM; Urtti A
    Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases.
    Jonas JB; Kreissig I; Degenring R
    Prog Retin Eye Res; 2005 Sep; 24(5):587-611. PubMed ID: 16005407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained transscleral drug delivery.
    Barocas VH; Balachandran RK
    Expert Opin Drug Deliv; 2008 Jan; 5(1):1-10. PubMed ID: 18095925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on recent drug delivery systems for posterior segment of eye.
    Nayak K; Misra M
    Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.